Efficacy of pembrolizumab monotherapy for advanced gingival malignant melanoma: A case report.

Oral malignant melanoma specifically denotes a rare subtype of melanoma originating in oral mucosa, characterized by a generally poor prognosis. Inhibitors targeting programmed cell death protein-1 or its ligand-1 (PD-1/PD-L1) have become widely accepted as primary treatments for malignant melanoma. The current report describes a unique case of advanced gingival malignant melanoma treated with pembrolizumab monotherapy in a 67-year-old Asian female. The report comprehensively evaluates the therapeutic potential of pembrolizumab, as well as its immune-related adverse events (irAEs).